Ignite Creation Date:
2024-05-05 @ 5:05 PM
Last Modification Date:
2024-10-26 @ 9:28 AM
Study NCT ID:
NCT00384852
Status:
COMPLETED
Last Update Posted:
2013-02-28
First Post:
2006-10-03
Brief Title:
A Study of rhBMP-2CPM in Closed Fractures of the Humerus
Sponsor:
Wyeth is now a wholly owned subsidiary of Pfizer
Organization:
Wyeth is now a wholly owned subsidiary of Pfizer
Study Overview
Official Title:
A Phase 2 Multicenter Double-Blind Randomized Stratified Controlled Efficacy Safety and Feasibility Study of Recombinant Human Bone Morphogenetic Protein-2 rhBMP-2Calcium Phosphate Matrix CPM as an Adjuvant Therapy in Closed Fractures of the Humerus
Status:
COMPLETED
Status Verified Date:
2013-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The primary objective of this study is to assess whether fracture union is accelerated in subjects with humeral fractures proximaldiaphyseal treated with conservative therapy standard of care and a single dose of rhBMP-2CPM compared to subjects who receive standard of care alone
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None